Skip to main content
Late-Breaking Research: PRACTICE MANAGEMENT RESEARCH
Abstract #LB01

Smart Solutions: Leveraging Artificial Intelligence in Investigational Drug Services

JHOP - March 2025 Vol 15 Special Feature - HOPA Abstracts
Travis Smith, PharmD, MBA; Alan Yee, PharmD, MS; Camille Walters, PharmD

Presenting Authors: Travis Smith, PharmD, MBA, Senior Manager–Research Pharmacy, Mayo Clinic, Rochester, MN; Alan Yee, PharmD, MS, Research Pharmacist, Mayo Clinic, Rochester, MN

Co-Author: Camille Walters, PharmD, Research Pharmacist, Mayo Clinic, Rochester, MN

BACKGROUND: Clinical research protocols are often complex, intricate, and lengthy documents and require the development of department-specific summaries to operationalize at the study site. Creating these summaries requires significant pharmacist time and effort. Incorporating artificial intelligence (AI) into this process may significantly decrease administrative burden and time while maintaining clinical accuracy.

OBJECTIVES: To assess the time required to complete pharmacy-specific study summaries manually versus AI-assisted and to assess the accuracy of documents created with AI assistance.

METHODS: As assessed by a scoring system, moderate- or high-complexity trials were eligible for inclusion. The time required for the manual preparation of pharmacy study summaries through usual workflow by the lead pharmacist for the study was recorded. Microsoft Copilot was prompted to complete a study summary template using the study protocol and pharmacy manual. The resulting AI-assisted summary was reviewed by an investigational drug service (IDS) pharmacist who was naïve to the study protocol. The time taken by an IDS pharmacist to complete the document was compared with the time taken by an IDS pharmacist assisted with AI. A mean difference of 20 minutes was defined as significant a priori. The number of corrections and grades of error were recorded for each study.

RESULTS: A total of 4 protocols were summarized manually and AI-assisted in parallel. The mean time to complete a study summary with AI assistance was significantly lower than manual summarization (35 minutes vs 167 minutes, respectively; P=.0296). There was an average 74% reduction in the time to complete the study summaries using AI-assisted workflow. Each initial prompt output required an average of 4.5 corrections.

DISCUSSION: In this case, the burden of time-consuming creation of documentation was mitigated by utilizing predesigned prompts to create standardized document output. Although manual reprompting and quality control were required to correct major errors, improvements in the prompt model and automation may further reduce manual effort.

CONCLUSION: The integration of AI into the clinical trial workflow significantly reduced the time to synthesize a study summary document when compared with traditional, manual processes.

Related Items
Evaluation of a Biosimilar Conversion in an Academic Medical Center Outpatient Infusion Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Outcomes of Supportive Care Versus Pharmacologic Intervention for the Management of CRS in Relapsed or Refractory Multiple Myeloma Treated With BCMA- and GPRC5D-Directed Bispecifics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
From Diagnosis to Decision-Making: Black Patient and Caregiver Perspectives on Lung Cancer Care and Support Needs
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Safety of Live-Attenuated MMR Vaccination in Patients With Multiple Myeloma Receiving Daratumumab After Autologous Stem-Cell Transplantation
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
A Real-World Analysis of Filgrastim and Biosimilars for Engraftment After Hemopoietic Cell Transplantation: Balancing Efficacy and Economics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Impact of an Oncolytic Pharmacist Prescription Verification Queue at an Academic Medical Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Talquetamab-Induced Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma: A Multicenter, Retrospective Study
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Phase 3 Study to Evaluate Efficacy and Safety of Pemivibart, an IgG1 Monoclonal Antibody, for the Prevention of COVID-19 (CANOPY): Subset Analysis of Participants With Chronic Lymphocytic Leukemia
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Safety of Shortened Postinfusion Observation Times for Pertuzumab and Ado-trastuzumab Emtansine: Retrospective and Prospective Analyses
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Real-World Incidence of Infusion-Related Reactions With Sacituzumab Govitecan and Opportunities for Premedication De-Escalation
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts